Moreover, genetic inactivation of the tumor suppressor NF2, a frequent tumorigenic event in mesothelioma, renders cancer cells more sensitive to ferroptosis, malignant mutations in NF2–YAP signaling can be used to predict the responsiveness of cancer cells to future ferroptosis-inducing therapy [56]. The gene discussed is NF2; the disease is mesothelioma.